COMMUNIQUÉS West-GlobeNewswire

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
10/09/2026
Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methods Dosing of additional patients with the new process at LyFE continues with [...]
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
10/09/2026
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX [...]
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
10/09/2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic [...]
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s [...]
LifeLabs Celebrates 11 Family Scholarship Recipients for 2026
10/09/2026
Toronto, Canada, Sept. 10, 2026 (GLOBE NEWSWIRE) -- LifeLabs, Canada's leading provider of laboratory diagnostic information and digital health connectivity systems, is proud to announce the outstanding recipients of [...]
Positioning ChemoMetec for future growth
10/09/2026
ANNOUNCEMENT NO. 313 10 September 2026 Annual Report 2025/26 (1 July 2025 - 30 June 2026) Positioning ChemoMetec for future growth Despite changes and uncertainty affecting ChemoMetec's markets, revenue grew by 3% to [...]
Guidance for the 2026/27 financial year
10/09/2026
ANNOUNCEMENT NO. 312 10 September 2026 ChemoMetec today approved the annual report for 2025/26, including the guidance for 2026/27, which is considered inside information. For the financial year 2026/27, ChemoMetec [...]
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
10/09/2026
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026
10/09/2026
Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 août 2026
10/09/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 août 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
10/09/2026
Lille (France), Cambridge (Massachusetts, United States), September 10, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver [...]
GENFIT annonce sa participation à la H.C. Wainwright 28th Annual Conference
10/09/2026
Lille (France), Cambridge (Massachusetts, États-Unis), le 10 septembre 2026 – GENFIT (Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie [...]
Adneuris Therapeutics Presents Novel Data on Lead Candidate, Cebranopadol for the Treatment of Moderate-to-Severe Acute Pain at PAINWeek 2026
10/09/2026
Adneuris unveiled new abuse potential data demonstrating that cebranopadol's abuse potential may be lower than that of Schedule II and Schedule IV pain drugs, further differentiating its dual NOP/MOP mechanism from [...]
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
10/09/2026
Company announcement – No. 47 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 10, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: [...]
Rad Source Technologies Introduces Sterile Insect Farms™
10/09/2026
Now offering Sterile Mosquitoes for Non-Chemical & Non-GMO Vector Control BUFORD, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rad Source Technologies, a leading innovator in X-ray solutions for life sciences, is proud [...]
Tecan to participate in upcoming Investor Conference
10/09/2026
Männedorf, Switzerland, September 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will participate in the following investor conference next week: 24 th Annual Morgan Stanley Healthcare [...]
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
10/09/2026
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001 in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an opportunity [...]
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
10/09/2026
Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Canada Steps Up to Support Global Cancer Care with First Contribution to IAEA’s Rays of Hope Initiative
10/09/2026
TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The Canadian Nuclear Isotope Council (CNIC) today announced Canada’s first official contribution to the International Atomic Energy Agency’s (IAEA) Rays of Hope initiative, a [...]

Pages